Skip to main content
. Author manuscript; available in PMC: 2012 Dec 8.
Published in final edited form as: Cancer Lett. 2011 Aug 6;311(2):219–229. doi: 10.1016/j.canlet.2011.07.023

Table 2.

Drug concentrations in normal tissue

Sample1 Irinotecan
Concentration
SN-38
Concentration

Concurrent schedule2 % change4
L. Intestine −20 −61
S. Intestine 19 −0.3
Bone marrow 20 −54***
Kidneys 9 −10
Liver 10 −14
Sequential schedule3 % change

L. Intestine 38 72
S. Intestine −19 67
1

Samples in concurrent schedule were taken 2h after treatments and 14d after treatment in the sequential schedule

2

MSC (0.2 mg/mouse) + irinotecan (100mg/kg)

3

MSC (0.2 mg/mouse/d) 7d prior to and then concurrently with irinotecan (100mg/kg × 2)

4

Compared to untreated controls

***

p<0.001 when compared with other groups